GSK plc simplifies ViiV Healthcare ownership as Pfizer exits and Shionogi raises stake
GSK completed a reshaping of ViiV Healthcare’s ownership on April 1, with Shionogi raising its stake to 21.7% after Pfizer exited the HIV-focused venture. ViiV issued new shares to Shionogi for $2.125 billion and cancelled Pfizer’s holding. GSK retained a 78.3% majority and took a $250 million special dividend. The deal extinguished a put option liability tied to the old structure.